Advances in Overcoming Immune Responses following Hemophilia Gene Therapy

Carol H. Miao

Seattle Children’s Research Institute & University of Washington, Seattle WA, USA

Abstract

Both clinical trials and pre-clinical experiments for hemophilia gene therapy showed that it is important to overcome potential immune responses against gene transfer vectors and/or transgene products to ensure the success of gene therapy. Recently various approaches have been investigated to prevent or modulate such responses. Gene transfer vectors have been specifically engineered and immunosuppressive regimens have been administered to avoid or manipulate the immune responses against the vectors. In order to prevent cytotoxic lymphocyte or antibody formation induced by transgene expression, novel approaches have been developed, including methods to manipulate antigen presentation, development of variant genes encoding less immunogenic proteins or gene transfer protocols to evade immune responses, as well as immunosuppressive strategies to target either T and/or B cell responses. Most of these successful protocols involve the induction of activated regulatory T cells to create a regulatory immune environment during tolerance induction. Recent development of these strategies to evade vector-specific immune responses and induce long-term immune tolerance specific to the transgene product will be discussed.

Keywords: Hemophilia; Gene therapy; Immune modulation; Regulatory T cells; Immunotherapy; Tolerance induction; Innate and adaptive immune responses

Introduction

Hemophilia A or B is congenital bleeding disorders caused by a deficiency of the blood clotting protein, factor VIII (FVIII) or factor IX (FIX), respectively; in its severe form, hemophilia is a life-threatening, crippling hemorrhagic disease. Recent development of efficient gene transfer technologies has promoted their application in hemophilia treatment. However from both pre-clinical experiments in animal models and human clinical trials, it is realized that immune responses against gene transfer vectors or transgene products can become major obstacles to the success of gene therapy [1-5].

Hemophilia patients have long been considered as an excellent candidate population for developing gene therapy approaches. This is due to the fact that current protein replacement therapy is very costly, and repeated infusions are required for both acute and prophylactic treatment. In addition, high risk of bleeding exists for the hemophilia patients and their disease resulting from a single factor deficiency can be corrected by a single gene addition. Previously, several phase I clinical trials have been attempted to treat hemophilia A patients [4-6]. However, only transient, low-level FVIII protein expression has been achieved, owing to inefficient gene transfer or impaired survival of transferred cells along with the possible development of immune responses against FVIII and/or associated gene transfer vectors. Similarly, phase I clinical trials for hemophilia B patients using retroviral vectors only produced transient FIX gene expression [7,8]. Subsequently, a study using adeno-associated viral (AAV) gene transfer of FIX into muscles cells was carried out in hemophilia B patients [9]. Long term gene expression was detected in the injection sites of the skeletal muscles, however, circulating FIX levels was generally below the therapeutic range [10]. In this case, gene transfer treatment was well tolerated and no antibodies to FIX were detected. To increase the efficacy of gene transfer, next trial was carried out using liver-directed, AAV-mediated gene transfer of FIX in hemophilia B patients [11]. Therapeutic levels of FIX was achieved initially, however, transgene expression declined at 6 weeks post hepatic gene transfer which correlated with a transient elevation of transaminase levels, indicating CTL responses against the transduced hepatic cells. T cell mediated immunity was also confirmed by the detection of AAV capsid specific CD8+ T cells in a treated patient with low titer of pre-existing antibodies to AAV-2. Most recently, gene therapy clinical trial for hemophilia using AAV serotype 8 (AAV8) vectors to deliver FIX gene into the liver achieved persistently 2 to 11% of normal FIX levels in six treated patients (2 patients each in 3 cohorts treated with high, intermediate, or low dose of vector) for 6 to 16 months [12]. Four patients did not require factor supplements; the other two required less prophylactic injections. However, of the other two patients in the high dose group, one had a transient, asymptomatic elevation of serum transaminase levels and did not achieve an initial therapeutic response. Low-titer neutralizing antibodies against AAV capsids were detected. The other one had a slight increase in liver enzyme levels, and the cause of which is unclear. Interestingly, following subsequent treatment of glucocorticoid therapy, the transaminase levels in both patients returned to normal and 3 to 11% of normal FIX levels were maintained [12]. In addition, no inhibitory antibody against FIX was detected in any of these patients. The long term responses from these patients are currently being followed [13].

From these clinical studies, it is clear that devising safe and effective methods to modulate immune responses is essential to ensure the success of hemophilia treatment. The development of novel immunomodulation strategies in animal models is discussed below.

Corresponding author: Carol H. Miao, Department of Pediatrics, Seattle Children’s Research Institute and University of Washington, 1900 Ninth Ave, C95-7, Seattle, WA 98101, USA, Tel: (206) 375-7588; E-mail: miao@u.washington.edu

Received November 20, 2011; Accepted December 21, 2011; Published December 23, 2011

Citation: Miao CH (2011) Advances in Overcoming Immune Responses following Hemophilia Gene Therapy. J Genet Syndr Gene Ther S1:007. doi:10.4172/2157-7412.S1-007

Copyright: © 2011 Miao CH. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Overcoming vector induced immune responses following hemophilia gene therapy

Following gene transfer, inflammation and innate immune responses against the gene delivery vectors (viral glycoproteins, RNA, and CpG DNAs, etc) and ensuing adaptive immune responses against specific viral proteins and/or transgene products can occur, resulting in induction of humoral responses and CTLs and killing of vector transduced cells. Various strategies have been investigated to avoid or manipulate the immune responses against specific gene transfer vectors.

Adeno-Associated viral vectors

As mentioned in the introduction, multiple clinical hemophilia B gene therapy trials have been carried out using AAV vectors. AAV vectors are nonpathogenic, replication-deficient, and elicit very weak innate immune responses. Long-term gene expression of FIX has been extensively demonstrated in mouse and dog models after muscle- or liver-directed gene transfer [14–17]. Nevertheless CTL responses to AAV capsid antigen especially in patients with pre-existing neutralizing antibodies against AAV remain a major road block to achieve persistent therapeutic correction for clinical application [11].

Recently multiple serotypes of AAV in addition to AAV2 have been developed; these serotypes carry different capsid proteins and exhibit different tropism towards different organs [18]. However these capsid proteins share high percentage of homology and may have significant crossreactivity with neutralizing antibodies raised against a particular serotype. Since AAV vectors remain mostly in episomal forms in transduced cells, it is uncertain if AAV will produce life-long transgene expression in vivo. If transgene expression declines over time, whether repeated treatment by AAV using different serotypes is feasible due to memory T cell immunity is currently unknown.

New strategies have been developed to combat these problems by modifying the capsid proteins. Alternative serotypes that do not contain a heparin binding site are less reactive with dendritic cells, thus activate CD8+ T cells less efficiently [19]. Domain shuffling of AAV capsids has been carried out to re-construct more efficient and less immunogenic capsid proteins [20,21]. Another strategy is to produce AAV capsids that can more rapidly uncoat/degrade inside the cells to reduce its immunogenicity. Proteasome inhibitor, bortezomib has been used to simultaneously enhance gene expression and decrease capsid antigen presentation on hepatocytes, thus decreasing the extent of immune activation of antigen-specific immune responses [22]. Furthermore, immunosuppressive protocol using mycophenolate mofetil (MMF) and cyclosporine A (CSA) was successfully applied to suppress T cell responses against the capsids at low vector dosages [23].

Recent reports by Herzog and others indicate that innate immune system also plays important roles in activation of immunity by AAV-mediated gene transfer, both in inducing the initial response to the vector and in promoting a deleterious adaptive immune responses [24,25]. The initial innate immune responses were mediated by the TLR9-MyD88 pathway via a traditional NF-κB pathway to induce innate immune responses [26]. These studies suggest that transient immunosuppression to block potentially detrimental signaling pathways mediating innate and adaptive immune systems may significantly improve the safety and efficacy of AAV-mediated gene therapy.

Adenoviral vectors

Adenoviral vectors have been studied intensively in gene delivery for hemophilia. Adenoviral vector particles can elicit both strong innate and adaptive immune responses. The interplay of both systems activates CD4+ and CD8+ T cells, and B cells, as well as facilitates the induction of transgene-specific immune responses; for example, administration of a FIX-adenoviral vector efficiently activated FIX-specific cytotoxic T lymphocytes (CTL) and generated FIX-specific antibodies [27,28]. Recent efforts have been made to reduce the immunogenicity of the vectors by development of new large capacity or gutted (devoid of all viral genes) vectors [29] or modification of capsid sequences [30,31]. However, even using a gutted vector, one major disadvantage is that adenoviral vectors can efficiently transduce APCs [32,33], which readily triggered innate immune responses and further augmented the induction of adaptive immune responses to the transgene product. This problem led to the introduction of tissue-specific promoters in gutted adenoviral vectors to restrict transgene expression in target cells but not in APCs [34]. Therapeutic levels of FVIII or FIX can be achieved using gutted adenoviral vectors with expression cassettes driven by a liver–specific promoter with limited toxicity in hemophilia mice [32,35] and dogs [36,37]. However, antibodies against transgene products eventually developed in several animals and transient hematologic and hepatic toxicities were observed in high-dose animal groups [37,38]. Subsequent phase I clinical trial achieved very low (~1%) levels of FVIII, which was stopped upon the detection of transient inflammatory response with hematologic and liver abnormality [6]. Strategies to further reduce the immunogenicity of adenoviral vectors are needed to evade the induction of strong immune responses against the transgene product. Localized injection of low vector doses into the liver by balloon occlusion catheter delivery helped further reduce the inflammatory and immune responses elicited by adenoviral vectors and led to long-term gene expression in nonhuman primates [39]. Transient non-specific immune suppressive regimens may also aid in reduction of the immunotoxicity of adenoviral vectors.

Retroviral/lentiviral vectors

Retroviral/lentiviral vectors are attractive for gene therapy since these vectors are devoid of all viral genes, integrate into the genome to yield persistent gene expression, and can accommodate relatively large genes [40]. Lentiviral vectors also had the added advantage of infecting non-dividing cells, which is superior than retroviral vectors for in vivo transduction of quiescent hepatocytes for hemophilia gene therapy. Transient therapeutic levels of FVIII or FIX were achieved following LV-mediated gene delivery into the liver [41,42]. Nevertheless, lentiviral vectors can efficiently interact with APCs and stimulate a rapid proinflammatory response. Rossetti and colleagues [43] found that delivery of lentiviral vectors induced strong innate immune responses via activation of pDCs and secretion of IFNaβ and TNF-α, leading to elimination of LV transduced cells. In another study [44], the innate responses induced in the cell culture system by LV transduction leading to activation of pDCs and IFNa secretion was found to be elicited not by LVs but by a particular tubulovesicular structures (TVS) derived from VSV-G transfected producer cells. Further in vivo testing of VSV-G pseudotyped vectors and elucidation of mechanisms triggering the innate host responses are needed for future human applications. LV pseudotyped with the GP64/Sendai envelope proteins may reduce macrophage transduction and help
activated FIX-specific cytotoxic T lymphocytes (CTL) and generated cytotoxic and humoral responses in hemophilia A mice [64,65].

Signals such as vector induced immunity, both cellular and humoral responses were detected in the absence of cellular immune [60] and nonviral naked plasmid vectors [61], only transgene-specific circulating FVIII activity, and subverted the effect of gene therapy. Immunocompetent hemophilia A mice and dogs, strong immune animal model systems. In many preclinical experiments using transgene product has been encountered in many gene therapy cases. Recently, modification of CpG sequences [58] or generation of CpG motifs of plasmids can be quite immunogenic in certain [57], therefore, CpG sequences [78] or generation of minicircle constructs [59] using optimized codon sequences can now be easily achieved to reduce/eliminate potential immune responses elicited by the naked DNA.

Overcoming transgene-specific immune responses following gene therapy

The problem of immune responses against exogenously introduced transgene product has been encountered in many gene therapy animal model systems. In many preclinical experiments using immunocompetent hemophilia A mice and dogs, strong immune responses against factor VIII (FVIII) have completely inhibited circulating FVIII activity, and subverted the effect of gene therapy. With less immunogenic vectors including adenoviral (AAV) [60] and nonviral naked plasmid vectors [61], only transgene-specific humoral responses were detected in the absence of cellular immune responses. Inhibitory antibodies were also observed following gene transfer of a VSVG-G pseudotyped, oncoretroviral vector encoding human BDD FVIII [62,63] and a FIV-based lentiviral-factor VIII vector [41] into hemophilia A mice. However, in the presence of other strong signals such as vector induced immunity, both cellular and humoral responses against transgene have been observed. Administration of an E1/E3 deleted adenoaviral vector encoding FVIII activated both cytotoxic and humoral responses in hemophilia A mice [64,65]. Similarly, an FIX-adenoviral vector mediated gene delivery efficiently activated FIX-specific cytotoxic T lymphocytes (CTL) and generated FIX-specific antibodies [27,28]. These results underline the importance of establishment of transgene-specific tolerance for achieving effective gene therapy treatment to treat specific diseases. Recently, many new approaches have been investigated to modulate transgene-specific immune responses. These new strategies are summarized in several categories.

Tolerance induction by recurrent exposures to antigens

Efforts have been made to induce tolerance by recurrent exposure to antigens before or at the onset of gene therapy. Hepatic gene transfer by AAV vectors resulting in persistent gene expression has been successfully used to induce immune tolerance to FVIII or FIX with or without transient immune suppression [66,67]. Recently AAV-mediated hepatic gene transfer prevented antibody formation against FIX in the easily immune-activated C3H/HeJ hemophilia B mice [68]. Moreover, liver-directed, AAV-mediated gene delivery of canine FVIII into hemophilia B dogs with pre-existing inhibitors completely eliminated the inhibitory antibody titers within several weeks post gene transfer, resulting in persistent cFVIII gene expression [69]. Another strategy is to induce tolerance before gene transfer such as recurrent oral or nasal administration of FIX proteins [70]. Similar strategies used to induce tolerance against FVIII in protein replacement hemophilia A mouse model may be also useful in gene transfer studies; these include repeated nasal or oral administration of FVIII-C2 domain or peptide(s) [71], infusion of lipopolysaccharide (LPS)-activated B-cell blasts transduced with a fusion IgG containing the C2 or A2 domains [72], FVIII pulsed immature dendritic cells [73,74], and apoptotic syngeneic fibroblast cells modified by FVIII expressing foamy vectors [75].

Methods to evade immune responses

Incorporation of tissue-specific promoters in gene transfer vectors: Efficient transduction of APCs can significantly promote the induction of transgene-specific immune responses. This has been observed particularly in adenoaviral and lentiviral vector-mediated gene delivery since both vectors transduce APCs quite efficiently. Incorporation of tissue-specific promoters to restrict transgene expression in the target tissue and reduce its expression in APCs can significantly minimize the occurrence of adaptive immune responses. Therefore, it is highly desirable to incorporate highly efficient, tissue-specific promoters in gene therapy vectors aiming at achieving high-level gene expression without undesired side effects and immune responses [16,32,50,76,77].

Incorporation of microRNA sequence in gene transfer vectors: MicroRNA (miRNA) is a newly discovered RNA group composed of ~21-23 nucleotide RNAs that negatively regulate gene expression at the post-transcriptional level. Since miRNAs have distinct expression profiles in different tissues, specific miRNA sequence was incorporated in gene transfer expression cassettes to further reduce transgene expression in APCs in combination with tissue-specific promoters. Recently a liver-specific lentiviral-FIX construct incorporating miRNA binding sites (mir-142-3p) specific for hematopoietic stem cells effectively suppressed residual transgene expression in APCs, leading to long-term FIX gene expression in hepatocytes without inducing anti-FIX immune responses [78]. Moreover, gene transfer by a miRNA regulated and GP64 pseudotyped Zent-FVIII vector driven by a liver-specific promoter prevented FVIII-specific antibody production after liver-directed gene therapy [47].

Generation of less immunogenic FVIII variants: It will also be desirable to generate a less immunogenic FVIII variant molecule.
However, any modifications on the FVIII molecule should not compromise the functional activity of FVIII. A BDD-FVIII/N6 variant [79] was found to produce lower anti-FVIII antibody titers than BDD-FVIII when delivered by either an adenoviral vector [80] or a plasmid vector [81]. Modifications of immunodominant T cell epitopes are also being investigated to reduce the immunogenicity of FVIII while maintaining its full functional activity [82].

**Neonatal gene transfer:** Some success have been achieved to evade antibody production and achieve persistent transgene expression following neonatal gene transfer of FVIII [63,77,83] and FIX [84,85]. Tolerance induction is found to be associated with antigen-specific CD4+CD25+Foxp3+ regulatory T cells (Tregs).

**Gene therapy targeting specific tissue or cell types:** Ex vivo transduction of hematopoietic stem cells by retroviral vectors were shown to induce partial tolerance to FVIII in some animals [86,87]. Recent improvement in the transduction protocol in combination with the use of a vector encoding a B-domain deleted porcine FVIII cDNA and immunosuppressive agents of CTLA4-Ig and anti-CD40L or anti-(murine)thymocyte serum (ATS), achieved therapeutic levels of FVIII long-term in a hemophilia A mouse model under a nonmyeloablative conditioning regimen for the establishment of a mixed chimerism [88]. Such a strategy was also effective even in mice with inhibitors to FVIII prior to HSC transplantation [89]. Ex vivo gene therapy using a lentiviral vector carrying the FVIII gene driven by platelet-specific alphaIIb promoter conferred FVIII gene expression in megakaryocytes [90,91]. The FVIII expressed was stored in platelets and only released at the site of platelet activation. The treated mice survived tail clipping assay and no anti-FVIII antibodies were detected. Platelet specific gene expression may be a way to evade the inhibitory antibody responses for treating hemophilia A. The current major obstacle for this protocol is the low level transgene expression and functional activity which need to be improved to ensure a therapeutic effect.

In addition, ex vivo gene therapy has been performed by implanting lentiviral vector transduced endothelial progenitor cells subcutaneously in a Matrigel scaffold in hemophilia A mice pretreated with tolerizing doses of FVIII and transient immunosuppression [92]. Therapeutic FVIII gene expression persisted for 27 weeks following transplantation before dropping to baseline levels due to the loss of implanted cells. None of the treated mice developed inhibitory antibodies to FVIII. Another group used a nanocapsule carrying the sleeping Beauty transposon system to direct FVIII gene into liver sinusoidal endothelial cells using [56]. Long-term (50 weeks) and high level (equal to normal level) gene expression of FVIII was achieved without apparent antibody formation along with improvement of hemophilia A phenotype in treated mice. Recently murine induced pluripotent stem (iPS) cells were generated and subsequently differentiated to both FVIII-secreting endothelial cells and endothelial progenitor cells and injected directly to the liver of irradiated hemophilia A mice. The recipient mice produced 8-12% FVIII levels and corrected the phenotype correction of murine bone marrow cells were transplanted directly into the host mouse livers. These cells subsequently transdifferentiated into liver cells including both hepatocytes and endothelial cells and produced approximately 20% normal levels of FVIII activities which persisted for more than a year without detection of anti-FVIII inhibitory antibodies [94].

**Immunosuppressive therapy targeting T cells**

Tolerance induction protocols involving antigen presentation and the methods to evade anti-FVIII immune responses often are successful in only a fraction of the treated patients or animals, and/or in combination with immunosuppressive agents. Therefore transient immunomodulation regimens to reduce or eliminate anti-FVIII inhibitory antibodies are highly desirable. Peripheral tolerance to a specific antigen can be induced through several different mechanisms by which to disrupt T cell activation or T and B cell interaction, or inhibit T or B cell function. In addition, dominant tolerance can be established through active suppression of activated effector T cells by Tregs.

**Common immunosuppressive drugs:** Common immunosuppressive drugs nonspecifically targeting T cell activation, clonal expansion or differentiation into effector T cells have been used to prevent antigen-specific responses. Cyclophosphamide has been used to suppress the immune response following FIX [76,95,96] and FVIII gene transfer [67,92,97]. In addition, cyclosporin A (CSA) suppresses the early stages of lymphocyte activation. Rapamycin (RAP) selectively suppresses activated T cells and favors expansion of Tregs. Mycophenolate mofetil (MMF) is an anti-proliferative agent for both B and T cells. Short-term immunosuppression with CSA in hemophilia B dogs prevented inhibitors following AAV-mediated gene delivery to the skeletal muscle [98]. Furthermore, a two drug therapy consisting of MMF and RAP [99] or MMF and FK-506 (tacrolimus) [100] prevented antibody response in AAV-mediated gene transfer of FIX into the liver of non-human primates. In addition, administration of 4 weeks, repeated dosing of FIX combined with RPA and interleukin (IL)-10 successfully prevented antibody formation and induced FIX-specific tolerance in hemophilia B mice following AAV-mediated gene therapy[This regimen induced substantial reductions in effector T cells (Teffs) and increases in Tregs. Nevertheless, in the FVIII plasmid gene therapy treated hemophilia A mice, application of either single-agent, or combined therapy with MMF, CSA, and RPA only resulted in delayed immune responses [97]. Inhibitory antibodies appeared quickly upon withdrawal of the drug(s).

**Blockade of costimulatory pathways:** Recently, monoclonal antibodies (mAbs) have emerged as a new class of immunosuppressive agents which appear to be both more effective and selective in facilitating immune tolerance induction; and are generally very well-tolerated by recipients. These agents targeting specific pathways also make them less toxic than non-specific, traditional immunosuppressive agents, and can induce antigen-specific tolerance in the presence of antigens. Monoclonal antibodies can be used to block the costimulatory pathway to induce T cell apoptosis or anergy. Multiple T cell costimulatory pathways, including CD28 and B7 molecules (CD80, CD86), ICOS and ICOSL, CD-40L and CD40, OX40 (CD134) and OX40-L, provide a functional network to ensure robust T cell activation to mount immune responses against foreign antigens.

Several agents to interrupt costimulatory pathways have been used to induce tolerance to FVIII. CTLA4-immunoglobulin (CTLA4-Ig) blocks the costimulatory interaction of B7 and CD28. It has been shown to transiently block the inhibitor formation in hemophilia A mice [102]. In relation to CTLA4-Ig, the part of its action at least in certain models is through the induction of indoleamine 2,3-dioxigenase (IDO), a triptophan degrading enzyme. Co-delivery of FVIII and IDO genes in a transposon system yielded long-term therapeutic FVIII expression and significantly reduced anti-FVIII antibody titers [103]. Similar to CTLA4-Ig, anti-CD40L has been shown to block the re-stimulation and differentiation of FVIII-specific memory B cells in the presence of FVIII antigen [104,105]. Dual blockade of CD40/CD40L and B7/CD28...
pathways using a combination regimen of anti-CD40L and CTLA4-Ig have been demonstrated to act synergistically to prevent antigen-specific immune responses and induce long-term tolerance to FVIII in FVIII plasmid-treated hemophilia A mice [97].

Anti-inducible co-stimulatory molecule (ICOS) blocks the third costimulatory pathway of interaction between ICOS and ICOS-ligand (ICOS-L). In the plasmid-treated hemophilia A mice, inhibitory antibody formation was successfully prevented following nonviral gene transfer of FVIII and anti-ICOS treatment [106]. Multiple phases of changes were observed including transient depletion of CD4+ T cells during initial treatment period, reduction of T effector cells, up-regulation of CD4+CD25+Foxp3+Tregs in terms of both percentage and activity, up-regulation of regulatory cytokines including interleukin-10 and transforming growth factor-β. These results indicated the involvement of antigen-specific regulatory T cells in tolerance induction. Furthermore, Anti-ICOS-treated mice tolerated hFVIII generated normal primary and secondary antibody responses after immunization with the T-dependent antigen, bacteriophage Φ x174, indicating maintenance of immune competency of the treated mice. Anti-ICOS which is currently under development for clinical applications represents a highly effective agent for modulating antigen-specific immune responses.

**T-cell depletion therapy:** Depletion of T cells and sometimes in combination of B cells can significantly reduce the number of effector T cells capable of mounting an immune response at the time of initial exposure to foreign antigens. Five consecutive anti-CD3 treatments concomitant with factor VIII plasmid injection prevented the formation of inhibitory antibodies against FVIII and achieved persistent, therapeutic levels of FVIII gene expression in treated hemophilia A mice [107]. Repeated plasmid gene transfer is applicable to tolerated mice without eliciting immune responses. It was demonstrated that FVIII-specific tolerance was induced by anti-CD3 treatment via a mechanism involving the increase in TGF-β levels and the generation of adaptive FVIII-specific CD4+Foxp3+ regulatory T cells in the periphery [107]. Depletion of effector T cells following anti-CD3 administration generated a suitable window for antigen-specific Tregs to proliferate and be activated.

**Adoptive regulatory T cell therapy:** A dominant tolerance can be induced by suppression of activated T cells by regulatory T cells. T cell homeostasis was achieved by balancing the CD4+CD25+ Tregs and effector T (Teff) cells; tolerance induction can be accomplished by inducing a balance shift between Treg and Teff cells. Recently, CD4+CD25+ Treg cell populations have been successfully induced and/or expanded, and shown to suppress autoimmune and alloimmune responses [108-111]. Adoptive transfer of Tregs isolated from FVIII-exposed HemA/Foxp3-Tg mice produced significantly reduced antibody titers in Treg recipient hemophilia A mice compared to untreated control mice after initial challenge with FVIII plasmid and second challenge 16 weeks post first plasmid treatment [112]. It was suggested that the adoptively transferred Tregs induced significant activation of endogenous Tregs in the recipient mice via an infectious tolerance mechanism, which was responsible for the long-term protective effect in vivo against FVIII-specific immune responses and limit recall responses induced by a second challenge. Adoptive transfer therapy of Tregs to modulate antigen-specific responses has many advantages over conventional treatments. Some of these benefits include: protection through antigen-specific activity without general immunosuppression, the possibility of inducing physiological long-lasting regulation in vivo, and customized therapy for individual patient with limited or no side effects.

**In vivo expansion of regulatory T cells:** Many successful approaches developed towards induction of tolerance to factor VIII (FVIII) and other antigens [113] involve suppressive function of Tregs. An in vivo approach for inducing selective expansion of T cells by injecting hemophilia A mice with IL-2 mixed with a particular IL-2 monoclonal antibody (mAb, JES6-1) [114] was used to modulate FVIII-specific immune responses. The mice treated with IL2/IL2mAb complex generated no inhibitory antibodies against FVIII and achieved therapeutic-level of FVIII gene expression in FVIII plasmid-treated mice [115]. The treatment led to a marked 5-7-fold increase in total numbers of Treg cells in the peripheral blood on the peak day (day 6 following the last IL2/IL2mAb complex treatment) and these levels gradually returned to normal within the next 7-14 days. These short-lived expanded Tregs are highly activated and display superior suppressive function. Little or no change in other cell populations was observed. Furthermore, IL2/IL2 mAb complexes can transiently reduce inhibitory antibody titers in mice with pre-existing inhibitory antibodies following gene transfer [115]. These results demonstrate the important role of Tregs in suppressing anti-FVIII immune responses and the potential of developing in vivo Treg expansion therapy to induce long-term tolerance to FVIII.

**Immunosuppressive therapy targeting B cells**

**Tolerogenic B-cell therapy:** David Scott’s laboratory has investigated a B cell therapy by using tolerogenic B cells transduced with a retroviral vector carrying the cDNA encoding the A2 or C2 domains of FVIII fused to the heavy chain of murine IgG to induce FVIII tolerance [72,116]. Specific tolerance to A2 or C2 domain was induced by this protocol. Furthermore, a combination of A2-IgG and C2-IgG expressing B cells induced tolerance to the full-length FVIII protein. This therapy successfully prevented antibody production in naive mice without inhibitors or reduced the inhibitor titers in FVIII-primed hemophilia A mice (mice with pre-existing inhibitors)[72]. Significant increase of Tregs was detected in B cell- transduced animals and depletion of CD4+CD25+ Tregs completely abolished the tolerance [117].

**B-cell depletion therapy:** Scott and colleagues [118] also studied the effect of B cell depletion on tolerance induction to FVIII. In FVIII primed mice, a single dose of IgG1 anti-CD20 pretreatment prevented the increase in inhibitor formation in the majority of treated mice receiving high dose protein replacement therapy. This antibody can selectively deplete follicular B cells while spare marginal zone (MZ) B cells as a potential tolerogenic antigen-presenting cells. Both of these therapies have implication on being potential immunomodulation strategies for regulating transgene-specific immune responses following gene therapy.

In FVIII plasmid-treated hemophilia A mice, it was found that administration of anti-murine CD20 IgG2a into hemophilia A mice significantly reduced CD19+ B cells in blood, spleen, and lymph node[119]. The depletion of B cells lasted for sustained periods of time and gradually returned to normal at ~8 weeks post anti-CD20 treatment. No significant change in the numbers or percentages of CD4+ T cells and CD4+CD25+Foxp3+ regulatory T cells was observed during the experimental period. Transient depletion of B cells induced tolerance to FVIII in a portion of the gene therapy treated hemophilia A mice. However, most of the mice eventually developed inhibitory antibodies. In these cases, depletion of B cells following gene transfer did not create a sufficient window for induction of tolerance in the presence of antigen. Anti-CD20 still represents a potential candidate in
therapies combined with other immunomodulation agents, especially in modulating pre-existing immune responses [120].

Perspectives

In order to achieve the goal of long-term transgene expression following gene therapy to treat genetic diseases, it is imperative to prevent or modulate the induction of immune responses to gene transfer vectors, gene modified cells, as well as transgene products. The immune system is complex and its defense can mount several layers of host responses to barricade the persistence of transduced cells and their transgene products. As discussed previously, once innate responses were initiated, it can not only trigger the destruction of transduced cells, but also prime the adaptive immune responses against the viral proteins and transgene products. These responses will ultimately destruct the vector transduced cells and/or neutralize the therapeutic protein. Some studies are finally designed to delineate the mechanism of each of these individual activation pathways and how they interplay. Some immunomodulation regimens discussed above may have impact on other responses. Effective therapy will need to be carefully evaluated depending on the vector system, the type of transgene, delivery route, target tissue, and other factors. Furthermore, safety profile will need to be considered by the following criteria: [1] require only transient exposure to immunosuppressive protocols; [2] induce minimal cytotoxicity and related associated toxicity; [3] exhibit minimal effects on immune competence; and [4] mediate antigen-specific long-term tolerance. Recent successes in the preventative therapies to reduce/eliminate immune responses in animal models brought us closer to clinical application of gene therapy for hemophilia, especially in the case of hemophilia A. In particular, transient immunomodulation regimens with minimum side effects and toxicity are highly promising strategies for patients at high risk of inhibitor formation. Some of these reagents are already used in the clinic and some of these are under development for clinical use. Several studies [107,121] also showed that transient immunosuppression did not hamper the immune system for long-term; immune responses to other antigens or pathogens can be successfully induced following subsequent challenges.

Furthermore, although it is best to develop a preventative therapy to suppress immune activation during gene therapy application, novel strategies are needed to achieve successful gene therapy in the presence of pre-existing immunity against viral proteins or transgene product. Only a few studies have addressed this more intricate problem. Combined therapies targeting distinct immune activation pathways may have a better chance to modulate pre-existing immunity and induce long-term tranergene-specific tolerance.

Acknowledgements

The author is grateful for the suggestions and help from Drs. David J. Rawlings and Hans D. Ochs. The author would also like to acknowledge the grant support from NIH/NHLBI R01 HL00409 and R01 HL02800, and a special project award from Bayer Hemophilia Foundation.

References


